B7-33 vs BPC-157
Emerging vs Extensively Studied
compatible No known negative interactions; different mechanisms of action with complementary tissue-repair and anti-fibrotic properties.
Molecular Data
B7-33 BPC-157
Weight ~4,000 Da 1,419.53 Da
Half-life Not well characterized <30 minutes
Chain — 15 amino acids
Type Single-chain peptide Pentadecapeptide
Key Benefits
B7-33
01 Potent anti-fibrotic activity across multiple organ systems
02 Improved vasodilation and vascular compliance
03 Cardioprotective effects and potential to attenuate cardiac remodeling
04 Much simpler to synthesize than native two-chain relaxin-2
05 Selective RXFP1 agonism with biased signaling profile
06 Preclinical efficacy in models of heart failure and fibrosis
BPC-157
01 Accelerated tendon, ligament, muscle, and bone healing
02 Localized tissue repair with direct targeting
03 Superior bioavailability
04 Anti-inflammatory effects
05 Angiogenesis promotion
06 Gastric and intestinal protection
Dosing Protocols
B7-33
100-250mcg / Once daily
Anti-fibrotic / Cardiovascular support 100-250 mcg 1x daily
BPC-157
250-500mcg / Once or twice daily
Tendon/Joint healing 250-500 mcg 1-2x daily
Serious injury 500-1000 mcg 2x daily
General healing 250-500 mcg 1-2x daily
Maintenance 250 mcg 1x daily
Side Effects
B7-33
Injection site reactions (redness, mild irritation)
Potential transient hypotension due to vasodilatory effects
BPC-157
Mild injection site redness
Injection site irritation
Possible mild digestive adjustment (oral)
Contraindications
Pre-existing hypotension or conditions exacerbated by vasodilation
Pregnancy or breastfeeding (no safety data available)
Concurrent use of potent antihypertensive agents without medical supervision
No human safety data exists -- all protocols are extrapolated from preclinical research
Active cancer (due to angiogenic effects)
Pregnancy or breastfeeding
Blood thinners (consult doctor due to angiogenesis)
WADA prohibited for competitive athletes
Research Evidence
B7-33 BPC-157
Status Emerging Extensively Studied
References 5 studies 8 studies
Latest — July 2025
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.